MSFT 435.0 0.7061% AAPL 230.65 -1.2924% NVDA 139.965 -0.9097% GOOGL 176.965 4.2934% GOOG 178.65 4.3882% AMZN 193.73 1.5197% META 594.31 0.1736% AVGO 177.28 -1.0935% TSLA 262.2401 1.0481% TSM 195.14 -0.914% LLY 831.501 -7.977% V 291.3 3.3418% JPM 224.685 0.8008% UNH 564.77 0.4696% NVO 113.15 1.0448% WMT 81.58 -0.1469% LVMUY 134.2 -1.4033% XOM 117.0342 -0.2096% LVMHF 670.0 -1.3008% MA 513.51 1.4281%

CryoCell International Inc

Healthcare US CCEL

7.45USD
1.63(28.01%)

Last update at 2024-10-30T18:49:00Z

Day Range

6.058.20
LowHigh

52 Week Range

2.697.25
LowHigh

Fundamentals

  • Previous Close 5.82
  • Market Cap48.73M
  • Volume249729
  • P/E Ratio19.60
  • Dividend Yield0.41%
  • EBITDA5.82M
  • Revenue TTM31.23M
  • Revenue Per Share TTM3.72
  • Gross Profit TTM 21.54M
  • Diluted EPS TTM0.30

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-11-30 2021-11-30 2020-11-30 2019-11-30 2018-11-30
Type yearly yearly yearly yearly yearly
Date 2022-11-30 2021-11-30 2020-11-30 2019-11-30 2018-11-30
Income before tax 3.32M 2.61M 5.04M 3.39M 3.62M
Minority interest - - - - 0.00000M
Net income 2.77M 2.08M 3.62M 2.29M -0.85482M
Selling general administrative 15.58M 14.63M 14.29M 14.89M 15.63M
Selling and marketing expenses - - - - -
Gross profit 21.54M 19.90M 21.49M 21.78M 20.68M
Reconciled depreciation 1.81M 1.33M 0.64M 0.40M 0.32M
Ebit 4.02M 4.00M 7.66M 5.06M 4.75M
Ebitda 6.27M 5.71M 7.64M 7.09M 5.07M
Depreciation and amortization 2.25M 1.71M -0.01922M 2.02M 0.32M
Non operating income net other - - -1.07826M 0.03M -0.02472M
Operating income 4.02M 4.00M 7.66M 5.06M 5.19M
Other operating expenses 25.88M 24.50M 24.14M 25.16M 24.44M
Interest expense 1.52M 1.38M 1.54M 1.70M 1.55M
Tax provision 0.55M 0.53M 1.41M 1.10M 4.47M
Interest income - - - - -
Net interest income -1.52177M -1.37893M -1.54402M -1.70345M -1.54690M
Extraordinary items - - - - 0.00000M
Non recurring - - 1.28M 2.33M 0.00000M
Other items - - - - 0.00000M
Income tax expense 0.55M 0.53M 1.41M 1.10M 4.47M
Total revenue 30.34M 28.88M 31.15M 31.82M 29.22M
Total operating expenses 17.08M 15.51M 14.48M 15.13M 15.90M
Cost of revenue 8.79M 8.99M 9.66M 10.04M 8.54M
Total other income expense net -0.70552M -1.39189M -2.62227M -1.67129M 0.39M
Discontinued operations - - - - 0.00000M
Net income from continuing ops 2.77M 2.08M 3.62M 2.29M -0.85482M
Net income applicable to common shares 2.77M 2.08M 3.62M 2.29M -0.85482M
Preferred stock and other adjustments - - - - 0.00000M
Breakdown 2022-11-30 2021-11-30 2020-11-30 2019-11-30 2018-11-30
Type yearly yearly yearly yearly yearly
Date 2022-11-30 2021-11-30 2020-11-30 2019-11-30 2018-11-30
Total assets 64.89M 60.66M 46.20M 42.89M 42.39M
Intangible assets 15.15M 16.21M 1.53M 1.25M 1.34M
Earning assets - - - - -
Other current assets 0.43M 0.71M 0.24M 0.26M 0.25M
Total liab 66.41M 56.48M 48.87M 49.84M 51.30M
Total stockholder equity -1.52430M 4.18M -2.66513M -6.95285M -8.90830M
Deferred long term liab - - - - 0.00000M
Other current liab 5.57M 8.01M 2.90M 2.09M 2.70M
Common stock 0.15M 0.15M 0.14M 0.14M 0.14M
Capital stock 0.15M 0.15M 0.14M 0.14M 0.14M
Retained earnings -21.63751M -16.73619M -18.81971M -22.44431M -25.32952M
Other liab 38.04M 34.79M 29.59M 28.55M 26.03M
Good will 1.94M 1.94M 1.94M 1.94M 1.94M
Other assets 23.66M 22.27M 21.92M 22.15M 22.55M
Cash 1.70M 8.26M 10.36M 6.54M 6.04M
Cash and equivalents - - - - -
Total current liabilities 19.48M 21.07M 16.41M 15.43M 15.43M
Current deferred revenue 9.59M 9.36M 9.18M 8.88M 8.37M
Net debt 9.91M -5.44197M -4.12071M 2.42M 6.90M
Short term debt 2.72M 2.21M 3.38M 3.10M 3.10M
Short long term debt 2.42M 1.90M 3.10M 3.10M 3.10M
Short long term debt total 11.61M 2.82M 6.24M 8.96M 12.94M
Other stockholder equity 19.96M 20.77M 16.02M 15.36M 15.94M
Property plant equipment 14.21M 4.15M 1.64M 1.85M 1.49M
Total current assets 9.61M 15.78M 18.56M 15.39M 29.54M
Long term investments 0.31M 0.31M 0.31M 0.31M 0.31M
Net tangible assets -18.62005M -13.96859M -2.66513M -10.14352M -12.19105M
Short term investments 0.02M 0.08M 0.09M 0.90M 0.88M
Net receivables 6.04M 5.25M 6.32M 6.10M 5.87M
Long term debt 8.58M - 2.84M 5.86M 9.84M
Inventory 0.85M 0.92M 0.93M 1.08M 16.04M
Accounts payable 1.61M 1.49M 0.96M 1.37M 1.26M
Total permanent equity - - - - 0.00000M
Noncontrolling interest in consolidated entity - - - - 0.00000M
Temporary equity redeemable noncontrolling interests - - - - 0.00000M
Accumulated other comprehensive income - - - - 0.34M
Additional paid in capital - - - - 0.00000M
Common stock total equity - - 0.14M 0.14M 0.14M
Preferred stock total equity - - - - 0.00000M
Retained earnings total equity - - -18.81971M -22.44431M -25.32952M
Treasury stock - - -20.56336M -20.56336M -19.57111M
Accumulated amortization - - - - 0.00000M
Non currrent assets other 9.92M 10.26M 11.56M 13.07M 0.11M
Deferred long term asset charges - - - - 0.00000M
Non current assets total 55.28M 44.88M 27.64M 27.50M 12.85M
Capital lease obligations 0.61M 0.92M 0.30M - 0.00000M
Long term debt total - - - - 0.00000M
Breakdown 2022-11-30 2021-11-30 2020-11-30 2019-11-30 2018-11-30
Type yearly yearly yearly yearly yearly
Date 2022-11-30 2021-11-30 2020-11-30 2019-11-30 2018-11-30
Investments -15.27964M -6.95117M 0.46M -0.02836M -0.13625M
Change to liabilities 5.07M 4.78M 0.68M -0.49174M -0.54658M
Total cashflows from investing activities -15.27964M -6.95117M 0.36M -0.69066M -11.28241M
Net borrowings 9.29M -4.10000M -3.10000M -4.10000M 5.54M
Total cash from financing activities 0.15M -3.07296M -5.00400M -5.13154M 5.71M
Change to operating activities 0.41M -0.66731M 0.67M -0.62788M 0.03M
Net income 2.77M 2.08M 3.62M 2.29M -0.85482M
Change in cash -6.55913M -2.09804M 3.82M 0.50M -0.23912M
Begin period cash flow 8.26M 10.36M 6.54M 6.04M 6.28M
End period cash flow 1.70M 8.26M 10.36M 6.54M 6.04M
Total cash from operating activities 8.57M 7.93M 8.47M 6.32M 5.33M
Issuance of capital stock - - - - -
Depreciation 1.81M 1.33M 0.64M 0.40M 0.32M
Other cashflows from investing activities - - - - -10.70000M
Dividends paid -7.67273M - - - 0.00000M
Change to inventory 0.49M 0.21M 0.45M -0.02742M 0.32M
Change to account receivables -1.72039M 0.53M -0.82859M -0.99712M -1.34777M
Sale purchase of stock -1.81991M -0.24938M 0.04M -0.99224M 0.17M
Other cashflows from financing activities 16.99M 1.28M -1.90400M -0.03930M 9.00M
Change to netincome -0.27434M -0.39736M 0.37M 1.24M 3.33M
Capital expenditures 17.17M 6.95M 0.45M 0.66M 0.65M
Change receivables - - -0.82859M -0.99712M -1.34777M
Cash flows other operating - - 3.71M 3.80M 4.01M
Exchange rate changes - - - - 0.00000M
Cash and cash equivalents changes - - 3.82M 0.50M -0.23912M
Change in working capital 4.25M 4.86M 3.76M 2.28M 2.43M
Stock based compensation 0.46M 0.30M 0.62M 0.40M 0.48M
Other non cash items 1.01M 1.00M 1.11M 2.47M 0.58M
Free cash flow -8.59581M 0.97M 8.02M 5.66M 4.69M

Peer Comparison

Sector: Healthcare Industry: Medical Care Facilities

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CCEL
CryoCell International Inc
1.63 28.01% 7.45 19.60 - 1.53 9.72 1.89 8.46
HCA
HCA Holdings Inc
1.77 0.49% 362.44 13.19 13.66 1.13 293.44 1.77 8.22
FSNUY
Fresenius SE & Co KGaA ADR
- -% 9.27 16.87 9.44 0.42 0.78 0.79 5.37
FSNUF
Fresenius SE & Co. KGaA
- -% 37.50 16.76 9.62 0.42 0.79 0.78 5.31
JDHIY
JD Health International Inc
- -% 3.81 62.50 35.97 0.30 2.32 0.16 3.90

Reports Covered

Stock Research & News

Profile

Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.

CryoCell International Inc

700 Brooker Creek Boulevard, Oldsmar, FL, United States, 34677

Key Executives

Name Title Year Born
Mr. David I. Portnoy Chairman & Co-CEO 1963
Mr. Mark L. Portnoy Co-CEO & Director 1964
Ms. Jill M. Taymans CFO & VP of Fin. 1970
Mr. Oleg Mikulinsky Chief Information Officer 1973
Dr. Joanne Kurtzberg M.D. Medical Director and Member of Medical & Scientific Advisory Board NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.